Next Article in Journal / Special Issue
Attitudes towards Social Networking and Sharing Behaviors among Consumers of Direct-to-Consumer Personal Genomics
Previous Article in Journal / Special Issue
A Method for Biomarker Directed Survival Prediction in Advanced Non-Small-Cell Lung Cancer Patients Treated with Carboplatin-Based Therapy
Article Menu

Export Article

Open AccessArticle
J. Pers. Med. 2013, 3(4), 263-274; doi:10.3390/jpm3040263

Rapid Collection of Biospecimens by Automated Identification of Patients Eligible for Pharmacoepigenetic Studies

1
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
2
Department of Biomedical Informatics, School of Medicine, Emory University, Atlanta, GA 30322, USA
3
Center for Health Research, Kaiser Permanente Georgia, Atlanta, GA 30305, USA
*
Author to whom correspondence should be addressed.
Received: 30 May 2013 / Revised: 4 September 2013 / Accepted: 10 September 2013 / Published: 26 September 2013
(This article belongs to the Special Issue Feature Paper 2013)
View Full-Text   |   Download PDF [410 KB, uploaded 26 September 2013]   |  

Abstract

Epigenetics plays an important role in regulating gene expression, and can be modified by environmental factors and physiological conditions. Studying epigenetics is a promising approach to potentially improving the diagnosis, prevention and treatment of human diseases, and to providing personalized medical care. However, the role of epigenetics in the development of diseases is not clear because epigenetic markers may be both mediators and outcomes of human diseases. It is particularly complicated to study pharmacoepigenetics, as medication use may modify the epigenetic profile. To address the challenges facing pharmacoepigenetic research of human diseases, we developed a novel design to rapidly identify, contact, and recruit participants and collect specimens for longitudinal studies of pharmacoepigenetics. Using data in real-time from electronic medical record systems, we can identify patients recently start on new medications and who also have a blood test. Prior to disposal of the leftover blood by the clinical laboratory, we are able to contact and recruit these patients, enabling us to use both their leftover baseline blood sample as well as leftover specimens at future tests. With treatment-naïve and follow-up specimens, this system is able to study both epigenetic markers associated with disease without treatment effect as well as treatment-related epigenetic changes. View Full-Text
Keywords: electronic medical record; epigenetics; DNA methylation; epigenome; pharmacogenomics; pharmacogenetics; pharmacoepigenomics; epigenetic epidemiology electronic medical record; epigenetics; DNA methylation; epigenome; pharmacogenomics; pharmacogenetics; pharmacoepigenomics; epigenetic epidemiology
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Sun, Y.V.; Davis, R.L. Rapid Collection of Biospecimens by Automated Identification of Patients Eligible for Pharmacoepigenetic Studies. J. Pers. Med. 2013, 3, 263-274.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top